Aroa Biosurgery (ASX:ARX) LT-Debt-to-Total-Asset : 0.06 (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Aroa Biosurgery LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Aroa Biosurgery's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.06.

Aroa Biosurgery's long-term debt to total assets ratio increased from Sep. 2023 (0.05) to Sep. 2024 (0.06). It may suggest that Aroa Biosurgery is progressively becoming more dependent on debt to grow their business.

Aroa Biosurgery LT-Debt-to-Total-Asset Historical Data

The historical data trend for Aroa Biosurgery's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aroa Biosurgery LT-Debt-to-Total-Asset Chart

Aroa Biosurgery Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

LT-Debt-to-Total-Asset

0.16

0.06

0.05

0.06

Aroa Biosurgery Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial					0.04	0.06	0.05	0.06	0.06

Aroa Biosurgery LT-Debt-to-Total-Asset Calculation

Aroa Biosurgery's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (A: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2024 )	/	Total Assets (A: Mar. 2024 )
	=	5.899	/	101.878
	=	0.06

Aroa Biosurgery's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	5.48	/	97.074
	=	0.06

Aroa Biosurgery (ASX:ARX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Aroa Biosurgery LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Aroa Biosurgery's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Aroa Biosurgery Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aroa Biosurgery Ltd (ASX:ARX) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

AROAF:USA

Address

64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022

Website

https://www.aroa.com

Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.

Aroa Biosurgery Headlines

No Headlines